Clinically useful monoclonal antibodies in treatment

Basiliximab and dacluzimab are antibodies to the IL2 receptor (CD25) expressed on activated T cells. They are used as induction therapy in renal transplantation.

Antibodies to CD3 (OKT3) are used in the treatment of renal transplant rejection.

Rituximab is an antibody to CD20 expressed on B cells and is used in B cell lymphomas.

Antibodies to CD154 (CD40 ligand - a molecule pivotal in T cell costimulation) had great promise in transplantation and autoimmunity. However, trials in humans have stopped after early work showed a high incidence of thrombosis, probably because CD154 is expressed on activated human platelets.

Antibodies to CD8 have not been used clinically.